Retia Medical develops advanced hemodynamic monitoring solutions centered on its Argos Cardiac Output Monitor and proprietary Multi-Beat Analysis (MBATM) algorithm. The Argos Monitor provides accurate, real-time cardiac output and hemodynamic data by analyzing multiple heartbeats and leverages a patient’s existing arterial line without requiring additional disposables. The system is designed for high-risk surgical and critically ill patients, enabling individualized, data-driven care to improve outcomes and lower costs. The next-generation Argos Monitor can be set up in less than one minute and detects important changes in a patient’s status to enable immediate clinical intervention. The company combines expertise in physiology, signal processing, data science, and computational algorithms to engineer its products. Retia will use the new funding to expand its commercial team and accelerate development of next-generation algorithms for guiding care for high-risk patients. Retia Medical is a medical device company based in East Lansing, Mich., developing a less-invasive system to monitor cardiac output and other key measures of the cardiovascular system. Its core platform technology was developed at Michigan State University. The company says the monitor can provide accurate measurements when patients go into shock. Retia was co-founded by Rama Mukkamala and CEO Marc Zemel. The company raised $7M in a Series A financing led by the Pritzker/Vlock family office. It intends to use the proceeds to complete product development, submit regulatory filings and launch its minimally invasive cardiac output monitor.

Total raised

$22M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2022